AstraZeneca plc (AZN) announced Friday that detailed results from an updated analysis of the Phase III CASPIAN trial showed IMFINZI in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
from RTT - Biotech https://ift.tt/3cfWKtA
via IFTTT
No comments:
Post a Comment